January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
3 citations
,
June 2018 in “Internal Medicine” Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
5 citations
,
April 2023 in “Drug Design Development and Therapy” Drug repositioning can save time and money but needs more support.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
39 citations
,
January 2010 in “Trends in Parasitology” Anticancer drugs like methotrexate and trimetrexate could be effective and safe for treating malaria at low doses.
5 citations
,
July 2007 in “PubMed” An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
1 citations
,
November 2011 in “Journal of AIDS & Clinical Research” Raltegravir may cause hair loss in some patients.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
October 2021 in “Journal of Investigative Dermatology” COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
October 2009 in “Nature Reviews Urology” 1 citations
,
March 2011 in “Hospital Pharmacy” Various medications and vaccines can cause serious side effects.
15 citations
,
July 2004 in “AIDS” Indinavir therapy can cause reversible skin, hair, and nail darkening.
October 1977 in “Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)” Mefloquine was generally safe at 500 mg weekly, but higher doses caused nausea and diarrhea.
March 2026 in “Preprints.org” DRDE-07 shows promise for treating skin diseases due to its favorable properties.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
1 citations
,
December 2020 in “Case reports in dermatological medicine” A patient with pemphigus vulgaris improved significantly after treatment for an additional viral skin infection.
7 citations
,
February 2023 in “Exploration of Medicine” Drug repurposing offers promising strategies to improve tuberculosis treatment despite challenges.
39 citations
,
January 1977 in “Dermatology” The treatment cleared psoriasis in some patients but caused side effects in most.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
2 citations
,
June 2020 in “AIDS” Recreational drug use can cause misdiagnosed conditions and drug interactions in HIV patients.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
4 citations
,
January 2021 in “Genetics and Molecular Biology” COVID-19 treatments and vaccines face challenges due to genetic differences in people and the virus.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
6 citations
,
December 2023 in “Lancet. Infectious diseases/The Lancet. Infectious diseases” SIM01 significantly reduced post-COVID symptoms and is safe.
21 citations
,
April 2018 in “The Journal of urology/The journal of urology” SER120 nasal spray effectively reduces nighttime urination and is safe for patients.
October 2023 in “Frontiers in Pharmacology” Research on HIV-1 capsid inhibitors has progressed significantly, with the U.S. leading in contributions.
October 2022 in “Amplla Editora eBooks” Tocilizumab might be an effective treatment for COVID-19.
1 citations
,
June 2020 in “Unisa Institutional Repository (University of South Africa)” Low power red laser with efavirenz can reduce HIV-1 infection to undetectable levels and improve diagnosis.